Al B. Benson, MD

Articles

Dr. Benson on the Complexity of Up-front Treatment in HCC

November 10th 2020

Al B. Benson, MD, discusses the complexity of up-front treatment in hepatocellular carcinoma.

Dr. Benson on Treatment for Patients With Resectable Colorectal Cancer

December 18th 2019

Al B. Benson, MD, professor of medicine, Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses treatment for patients with resectable colorectal cancer (CRC).

Dr. Benson on MSI Testing in Colorectal Cancer

December 10th 2019

Al B. Benson, MD, discusses the implications of microsatellite instability testing on patients with colorectal cancer.

Dr. Benson on the Ongoing Research With Immunotherapy in mCRC

December 3rd 2019

Al B. Benson, MD, professor of medicine, Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses ongoing research with immunotherapy in metastatic colorectal cancer (mCRC).

Dr. Benson on Frontline Treatment Considerations in mCRC

November 1st 2019

Al B. Benson, MD, discusses key considerations in the frontline treatment of patients with metastatic colorectal cancer.

Dr. Benson on Sequencing Strategies with Cetuximab in CRC

October 25th 2019

Al B. Benson, MD, discusses the optimal sequencing of the EGFR inhibitor cetuximab for patients with RAS wild-type colorectal cancer.

Dr. Benson on the Use of Genomic Testing in Newly Diagnosed mCRC

October 22nd 2019

Al B. Benson, MD, discusses the use of genomic testing in patients with newly diagnosed metastatic colorectal cancer.

Dr. Benson on Considerations for Advanced CRC Treatment

December 12th 2018

Al B. Benson, MD, professor of medicine, Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses the factors to consider when approaching treatment for a patient with advanced colorectal cancer.

Dr. Benson on the Clinical Utility of cfDNA in Colorectal Cancer

November 16th 2018

Al B. Benson, MD, professor of medicine, Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses the clinical utility of cell-free DNA (cfDNA) in guiding treatment decisions for patients with colorectal cancer (CRC).